The applied testing markets will represent a $5 billion opportunity by 2008, and Qiagen expects its preanalytical technologies to play a significant role in that segment, CEO Peer Schatz said during a presentation to analysts and investors in New York last week.

Even though these markets currently represent around half of Qiagen's total sales, Schatz said the firm will remain primarily focused on growing its molecular diagnostics business.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

NPR reports that with medical data being big business, some companies want to get patients involved.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.